1. Introduction
Over the past few decades, polymeric drug delivery systems have become central to the advancement of modern therapeutics, providing a means to improve drug solubility, stability, and controlled release. Among the most extensively studied are poly(lactic-co-glycolic acid) (PLGA) and its polyethylene glycol (PEG)-modified derivatives (PLGA-PEG), which offer biocompatibility, biodegradability, and tunable properties suitable for diverse therapeutic applications (Anderson & Shive, 1997; Milacic & Schwendeman, 2014). These polymers are especially valuable for encapsulating drugs that face solubility or stability challenges, including small molecules, proteins, and hydrophobic compounds (Agrawal et al., 2006; Costa et al., 2025).
PEGylation of PLGA adds further versatility by modifying surface properties, reducing protein adsorption, and extending systemic circulation times, thereby enhancing drug bioavailability and therapeutic efficacy (Allen & Cullis, 2004; Almoustafa et al., 2017). The proportion and molecular weight of PEG, as well as the polymer block architecture (di-block vs. tri-block), have been shown to significantly influence particle size, encapsulation efficiency (EE), and drug loading capacity (LC), as demonstrated in studies with lysozyme, trimethoprim, aclacinomycin A, and simvastatin formulations (Milacic & Schwendeman, 2014; Zhou et al., 2025; Sulaiman et al., 2019).Encapsulation efficiency and drug loading are critical parameters that determine the therapeutic potential of polymeric nanoparticles. Encapsulation efficiency represents the fraction of drug successfully incorporated into the polymer matrix, while drug loading reflects the actual drug content relative to the total particle mass. These parameters are highly sensitive to polymer composition, molecular weight, PEG content, and particle size (Milacic & Schwendeman, 2014). For instance, in lysozyme-loaded PLGA-PEG formulations, minor variations in PEG proportion (10% vs. 15%) or polymer architecture (di-block vs. tri-block) were shown to affect both particle size and EE, emphasizing the importance of careful formulation optimization (Milacic & Schwendeman, 2014). Similarly, trimethoprim-loaded nanoparticles demonstrated that PEG molecular weight could reduce particle size and enhance EE, highlighting the interplay between polymer properties and functional outcomes (Zhou et al., 2025).
Controlled drug release and polymer degradation are fundamental to the clinical utility of PLGA-PEG systems. Drug release occurs via polymer erosion, diffusion through the matrix, or a combination of both, often influenced by additives such as magnesium carbonate (MgCO3) (Milacic & Schwendeman, 2014). Protein therapeutics such as lysozyme require precise release control to maintain bioactivity. For example, formulations containing MgCO3 exhibited continuous release of lysozyme over four weeks, whereas other formulations released the protein rapidly within three days, demonstrating how subtle differences in composition dramatically impact release kinetics (Milacic & Schwendeman, 2014).Factorial and statistical design approaches have been instrumental in optimizing PLGA-PEG formulations. Simvastatin-loaded PLGA-PEG-PLGA tri-block micelles, for example, were optimized by evaluating factors such as lactic acid-to-glycolic acid ratio and PEG content, which significantly affected particle size, polydispersity index (PDI), solubility, and EE (Sulaiman et al., 2019). Factorial analysis not only identifies the most influential factors but also elucidates complex interaction effects, which are often non-linear and critical for predicting release behavior and stability.
Degradation kinetics of PLGA-PEG polymers further modulate drug release. These polymers degrade via hydrolysis of ester bonds, producing lactic and glycolic acids that are metabolized naturally in the body (Anderson & Shive, 1997; Milacic & Schwendeman, 2014). Degradation rates are influenced by molecular weight, PEG content, particle size, and additives such as MgCO3, which act as buffers and stabilize labile drugs during release (Milacic & Schwendeman, 2014). Drug release profiles often follow sigmoidal patterns with initial lag phases, accelerated release periods, and final plateaus, reflecting the interplay between diffusion and erosion mechanisms.The clinical relevance of PLGA-PEG systems is significant. Drugs with narrow therapeutic windows, including trimethoprim, simvastatin, and aclacinomycin A, benefit from sustained release formulations that maintain therapeutic concentrations, reduce dosing frequency, and minimize adverse effects (Costa et al., 2025; Zhou et al., 2025). For proteins, controlled release reduces denaturation and aggregation, preserving bioactivity and minimizing immunogenic responses (Milacic & Schwendeman, 2014).Despite these advancements, challenges remain in achieving reproducible, scalable, and stable PLGA-PEG formulations. Issues such as particle heterogeneity, burst release, and protein stability during encapsulation require systematic evaluation (Bittner et al., 1999; Sulaiman et al., 2019). Meta-analytical approaches offer a robust framework for synthesizing data across studies, identifying formulation factors with significant effects, and revealing knowledge gaps for future research. By combining data on polymer composition, particle size, EE, LC, release kinetics, and degradation behavior, a meta-analysis provides evidence-based guidance for rational formulation design.



